Clinical outcomes of placenta previa with and without coverage of a uterine scar: A retrospective cohort study in a tertiary hospital

CURRENT STATUS: UNDER REVIEW

BMC Pregnancy and Childbirth  BMC Series

Jiaming Rao
Foshan Women and Children's Hospital Affiliated with Southern Medical University

Dazhi Fan
Osaka Boshi Iryo Center

Zixing Zhou
Foshan Women and Children's Hospital Affiliated with Southern Medical University

Gengdong Chen
Foshan Women and Children's Hospital Affiliated with Southern Medical University

Huiting Ma
Foshan Women and Children's Hospital Affiliated with Southern Medical University

Dongxin Lin
Foshan Women and Children's Hospital Affiliated with Southern Medical University

Shuzhen Wu
Foshan Women and Children's Hospital Affiliated with Southern Medical University

Xiaoling Guo
Foshan Women and Children's Hospital Affiliated with Southern Medical University

Zhengping Liu
Southern Medical University Affiliated Maternal & Child Health Hospital of Foshan

liuzphlk81@outlook.com Corresponding Author
ORCID: https://orcid.org/0000-0002-4964-0258

DOI: 10.21203/rs.2.13946/v1

SUBJECT AREAS
Maternal & Fetal Medicine
KEYWORDS

Placenta Previa; Placenta Accrete; Pregnancy Outcomes; Uterine Scar; hysterectomy; caesarean section
Abstract

Background

To compare the maternal and neonatal outcomes of placenta previa (PP) with and without coverage of a uterine scar in China.

Methods

A retrospective cohort study comparing all singleton pregnancies with PP was conducted at a tertiary, university-affiliated medical center between January 2012 and April 2017. Maternal and neonatal outcomes of PP with and without coverage of a uterine scar were compared.

Results

There were 58,062 deliveries during the study period, of which 738 (1.27%) were complicated PP in singleton pregnancies and were further classified into two groups: the PP with coverage of a uterine scar group (PPCS, n=166) and the PP without coverage of a uterine scar group (Non-PPCS, n=572). Overall, the PPCS group had poorer maternal and neonatal outcomes for premature birth (< 37 weeks, 68.1% vs 54.8%; P=0.010), cesarean section (100% vs 97.6%; P=0.042), Intraoperative blood loss > 1000 ml (78.3% vs 16.0%; P<0.001) or > 3000ml (29.5% vs 3.0%; P<0.001), postpartum hemorrhage (48.8% vs 15.7%; P<0.001), transfusion (35.2% vs 16.1%; P<0.001), hemorrhage shock (8.4% vs 1.9%; P<0.001), hysterectomy (3.0% vs 0.5%; P=0.006) and fetal distress (36.1% vs 12.0%; P<0.001) than the Non-PPCS group. In pregnancies complicated without abnormal invasive placenta (AIP, n=587), the PPCS group had poorer maternal and neonatal outcomes for Intraoperative blood loss > 1000 ml (69.0% vs 12.5%; P<0.001) or > 3000ml (9.2% vs 1.0%; P<0.001), bleeding within 2-24 hours after delivery (114.7±283.9 vs 47.7±45.1 ml, P<0.001), postpartum hemorrhage (70.1% vs 15.2%, P<0.001), transfusion (28.7% vs 13.6%, P<0.001) and fetal stress (35.6% vs 11.4%, P<0.001) than the Non-PPCS group.

Conclusion

The PPCS group had poorer maternal and neonatal outcomes than the Non-PPCS group. Women with PPCS were more likely to have intraoperative and postpartum hemorrhage, transfusion and fetal distress, even without AIP.
Background
Placenta previa (PP) is defined as implantation of the placenta in the lower uterine segment overlying the endocervical os, and it is known as an important cause of serious fetal and maternal morbidity, even mortality [1, 2]. PP is associated with an increased risk of bleeding, blood transfusion, postpartum anemia, hysterectomy, septicemia, thrombophlebitis and maternal death [3-5]. A population-based study [6] noted that 44.4% of patients with PP delivered before 37 weeks of gestation, 16.9% of these delivered before 34 weeks of gestation, and neonatal mortality rates were increased by threefold to fourfold.

The incidence of PP was higher in Asia (1.2%) and lower in Europe (0.36%), North America (0.29%) and sub-Saharan Africa (0.27%) [7]. Our previous research showed that the incidence of PP was between 0.93% and 2.01% in mainland China [8]. The incidence of PP has increased, probably due to the increasing rates of cesarean delivery, maternal age, and assistive reproductive technology. Certainly, there is a dose–response relationship between the number of previous cesarean sections and subsequent placenta previa. Thus, although the etiology of placenta previa remains indeterminate, there appears to be a link between endometrial damage and uterine scarring and subsequent placenta previa.

In general, PP is subdivided into three categories according to the position of the placenta and the cervix: complete previa, marginal previa, and partial previa. However, PP is particularly dangerous when covering a uterine scar (PPCS). PPCS, also called pernicious placenta previa (PPP), one of the most dangerous types of PP, was proposed by Chattopadhyay et al [9] and defined as when the placenta overlies a uterine scar that may or may not with accreta. The incidence of PPCS has increased correspondingly with the increase of cesarean section in China and often leads to unexpected bleeding during delivery and increased risk for peripartum hysterectomy [10-12].

A large number of previous studies have reported the clinical outcomes and associated risk factors of PP [5, 9-11, 13-15], and only a few reports have focused on comparing PPCS and Non-PPCS [12, 16]. This information on these conditions is important to know so that women with a specific type of PP can be appropriately counseled regarding their outcomes, and physicians can be appropriately
prepared for their deliveries. Thus, the specific objective of this study was to investigate the maternal and neonatal outcomes of women with PPCS and Non-PPCS in a Chinese cohort.

Materials And Methods

Study design and population

A retrospective cohort study comparing pregnancies with PP with and without coverage of a uterine scar was conducted over 24 weeks. This hospital was a tertiary university-affiliated medical center with a stable number of approximately 13,000 deliveries per year, which accounted for approximately 10% of the city's deliveries and provided care for the region's obstetrical population, especially those with complicated pregnancies. There were 58,062 pregnancies who delivered a liveborn or a stillborn infant of at least 24 gestational weeks at our hospital during the period of January 2012 to March 2017, and 738 women who had complicated PP with a singleton pregnancy were included for further study (Figure 1). All data were retrospectively analyzed from the electronic medical records, surgical records and anesthetic records. Exclusion criteria included multiple pregnancies, misdiagnosis or fetal malformation; not delivering in the study hospital and no archive in the hospital electronic system; or loss of information regarding placental position. The study was approved by the Human Subjects Committee of the Southern Medical University Affiliated Maternal & Child Health Hospital of Foshan. To ensure patient privacy, our data did not include the patient’s name, phone number, home address, or other sensitive information.

PP is defined as implantation of the placenta in the lower uterine segment in advance of the fetus, including complete placenta previa, partial placenta previa and marginal placenta previa. Low-lying placenta previa was excluded in our study because of its different clinical management [17]. In this study, the patients with PP were divided into two groups: the placenta previa with coverage of a uterine scar group (PPCS group, n=166 cases) and the placenta previa without coverage of a uterine group (Non-PPCS group, n=572 cases). PPCS was defined as PP where the placenta covered a uterine scar in the lower uterine segment. Non-PPCS was defined as PP where placenta did not cover a uterine scar in the lower uterine segment. The placental position was divided into 3 groups: anterior, posterior, and ante-posterior or laterally positioned. The placental position was evaluated in a
transverse cross-section by ultrasound or MRI, in which the maximum placental area was depicted. Anterior placenta is a placenta dominantly attached to the anterior wall of the uterus, and a posterior placenta is a placenta dominantly attached to the posterior wall of the uterus. The other placentas were defined as ante-posterior or laterally positioned. All types of PP were diagnosed by experienced obstetricians, based on serial transvaginal or transabdominal ultrasonographic scans or MRI, and confirmed at the time of delivery.

Definitions
The following clinical characteristics were evaluated in all patients: maternal age, BMI, gestational weeks, race/ethnicity, parity, prior CS, mode of delivery, in vitro fertilization and embryo transfer (IVF-ET) or not, diseases associated with pregnancy (diabetes or gestational diabetes mellitus, hypertension disorder complicating pregnancy). To compare maternal and neonatal outcomes, gestational weeks, mode of delivery (vaginal, CS), postpartum hemorrhage, postpartum anemia, hysterectomy, number of days in the hospital, hospitalization expenses, infant weight, intrauterine death, fetal distress, Apgar score at 1 min, and Apgar score at 5 min were compared in the two groups. We calculated gestational age on the basis of the actual delivery date in the medical record. PPH was diagnosed according to blood loss of more than 500 ml for vaginal deliveries and more than 1000 ml for cesarean delivery by the American College of Obstetricians and Gynecologists (ACOG) [18]. Postpartum anemia was defined as a hemoglobin concentration of <110 g/L (6.8 mmol/L) according to WHO [19]. HDCP (systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥ 90 mmHg, with or without proteinuria) can be classified into five groups: (1) gestational hypertension, (2) preeclampsia, (3) eclampsia, (4) superimposed preeclampsia on chronic hypertension and (5) chronic hypertension in pregnancy preeclampsia [20]. GDM was diagnosed when one of the following conditions was met: (1) fasting plasma glucose ≥ 5.1 mmol/L two or more times; (2) two or more test results equal to or above the following values after a 75 g-load OGTT: fasting, 5.1 mmol/L; 1-hour, 10.0 mmol/L; 2-hour, 8.5 mmol/L.

Statistical analysis
Categorical data were reported as numbers and percentages (%), and descriptive data were
expressed as the means ± standard deviations (SD). Boxplots describe the amount of bleeding between groups by using the median, the upper quartile, and the lower quartile. The 95% confidence intervals or interquartile range were calculated and presented. Statistical significance was calculated using a Chi-square test or Fisher’s exact test for differences in qualitative variables and a t test for differences in continuous variables. Statistical analyses were performed with the Statistical Package for Social Science Version 22.0 (SPSS Inc, Chicago, IL, USA) and R (3.4.1). Two-tailed P values <0.05 were considered statistically significant.

Results

There were 58,062 pregnant women who delivered a liveborn or a stillborn infant of at least 24 gestational weeks at our hospital during the period of January 2012 to March 2017, and 738 women had complicated PP with a singleton pregnancy and were identified for further data review (Figure 1). Of these 738 women, 166 (22.5%) had PPCS and 572 (77.5%) had Non-PPCS. The clinical characteristics of the groups are shown in Table 1. The mean age of individuals with pregnancies complicated with PP was 31.71 ± 5.25 years old, the mean BMI was 26.06 ± 3.11, and the mean number of gestational weeks was 35.70 ± 2.46 weeks. Most of the women were Han Chinese (98.4%), 31.3% were primipara and 8.3% had a pregnancy with IVF-ET. PPCS was significantly associated with advanced maternal age, higher than average BMI, greater parity and prior CS compared with Non-PPCS. There were no significant differences in gestational weeks, IVF-ET, HDCP and diabetes or GDM between the two groups. PPCS was significantly associated with a higher proportion of AIPs (47.6% vs 12.6%, P< 0.001) and placenta increta or percreta (37.3% vs 5.6%, P<0.001) compared to Non-PPCS (Table 2). There was no significant difference between the two groups in the number of women with placenta accreta (10.2% vs 7.0%, P =0.168). The PPCS group was dominated by anterior placentas (46.4%), followed by ante-posterior or laterally positioned (34.3%) and posterior placentas (19.3%), while the Non-PPCS group was dominated by posterior placentas (56.1%), followed by ante-posterior or laterally positioned (21.9%) and anterior placentas (21.9%).

In pregnancies complicated with AIP (n=151, Table 3), the PPCS group was associated with poor
maternal outcomes for intraoperative blood loss (3000 [1500,4500] ml vs 700[400,1500] ml, 
P<0.001, Figure 2) and bleeding within 2-24 hours after delivery (209.9±415.2 ml vs 65.5±114.2 ml, 
P=0.008) and with greater hospitalization expenses (29756±9849 vs 18359±8712, CNY, P=0.008) 
than the Non-PPCS group. The Non-PPCS group was associated with a higher incidence of postpartum 
anemia (41.7% vs 24.1%, P=0.021) and higher APGAR scores at 5 min (9.7±1.3 vs 9.1±1.6, P=0.035) 
than the PPCS group. There was no significant association between the PPCS group and the Non-PPCS 
group in the rates of CS, postpartum hemorrhage, transfusion, hemorrhagic shock, hysterectomy and 
number of days in the hospital.

In pregnancies not complicated with AIP (n=587, Table 3), the PPCS group was associated with poor 
maternal outcomes for intraoperative blood loss (1100 [800,1750] ml vs 400[300,600] ml, P<0.001, 
Figure 2), bleeding within 2-24 hours after delivery (114.7±283.9 vs 47.7±45.1 ml, P<0.001), 
postpartum hemorrhage (70.1% vs 15.2%, P<0.001), transfusion (28.7% vs 13.6%, P<0.001), and 
fetal stress (35.6% vs 11.4%, P<0.001) and with greater hospitalization expenses (20920±7197 vs 
13220±8242, CNY, P<0.001) than the Non-PPCS group. There was no significant association between 
the PPCS group and Non-PPCS group in the rates of CS, hemorrhagic shock, postpartum anemia, 
hysterectomy, number of days in the hospital, mean infant weight, intrauterine death and Apgar score 
at 1 and 5 min.

Discussion

Principal findings of this study

Prior studies have shown that PP was significantly associated with a range of adverse outcomes for 
both mothers and neonates; however, comparisons of PP with and without coverage of a uterine scar 
were rarely reported. Thus, the aim of our study was to investigate the maternal and neonatal 
outcomes of PPCS and Non-PPCS in a Chinese cohort. This large retrospective cohort study of 738 
women with PP between January 2012 and March 2017 found that the PPCS group had poorer 
maternal and neonatal outcome for intraoperative blood loss, bleeding within 2 – 24 hours after 
delivery, postpartum hemorrhage, transfusion and fetal distress than the Non-PPCS group, even after 
being grouped according to whether they were complicated with AIP. Overall, infant weight,
intrauterine death, postpartum anemia, oligohydramnios and number of days in the hospital were not associated with the incidence of PPCS.

China’s family planning policy has been in place for more than three decades, and most couples have been restricted to only one child since 1980. Many pregnant women have had a primary cesarean section on account of only one child being allowed. Rising primary cesarean delivery rates strongly affect maternal mortality rates due to the increase of placenta previa and accreta after multiple cesareans. With the rapid growth of the aging population, China relaxed its more than three-decade-old family planning policy and allowed a couple to have two children. A survey of maternal and child health in Asia by the WHO showed that the rate of cesarean section in China was 46.2% in 2010, which is the three times (15%) the WHO’s recommended upper limit [21]. Another study [22] recently found that the cesarean section rate rose from 28.8% in 2008 to 34.9% in 2014. However, this proportion varies widely in the 31 provinces of China from 4% to 62.5% in 2014. The high cesarean delivery rate is associated with an increased risk of placenta previa in subsequent pregnancies. This risk of PP rises as the number of prior cesarean sections increases. With the implementation of the universal two-children policy in China, there will be more multipara with a scarred uterus and PPCS in the future.

PP is suspected and diagnosed in approximately 5% of pregnancies between 15 and 16 weeks [23], and almost 90% of PP resolves to a normal position by term [24], which may be explained by the elongating of the uterus and the gradually rising position of the placenta away from the cervix with increasing gestational age. However, such a mechanism will be interfered with if the placenta is covered in uterine scarring from a previous CS such that the placenta cannot move normally.

Moreover, our data showed that nearly half (47.2%) of PPCS pregnancies combined with AIP, suggesting that we should do detailed prenatal check-ups, including ultrasound and MRI when we find this condition in clinical practice, to determine the likelihood of placenta implantation, location and depth of placenta accreta.

The correlation between gestational age and different types of placenta previa remains controversial. Some studies reported no differences in gestational age at delivery of infants born to mothers with
different types of placenta previa [10, 25]. However, more studies agreed that premature delivery was more frequent in women with complete placenta previa [17, 26], but the comparison of preterm birth rates between infants with mothers with PPCS and Non-PPCS is rarely reported. Our results found that premature birth remains a major problem, with 54.8% of infants born prematurely to women in the Non-PPCS group and 68.1% of infants born to women in the PPCS group. Some studies have addressed whether types of placenta previa are associated with the severity of symptoms in mothers and neonates, but data aimed at understanding PPCS were insufficient. Our results show that women with PPCS had a higher rate of CS, postpartum hemorrhage, transfusion, and hysterectomy and that the infants born to women with PPCS had lower Apgar scores at 1 and 5 min. Specifically, women in the PPCS group are at an approximately 3-fold (48.8% vs 15.7%) increased risk of postpartum hemorrhage, and 6-fold (3.0% vs 0.5%) increased risk of hysterectomy than women in the Non-PPCS group. Additionally, the presence of accreta is often the factor that determines a change in clinical management and outcome. We divided the subjects into an AIP group and non-AIP group and found that obstetric hysterectomy was performed in 6.3% and 2.8% of the women with PPCS and Non-PPCS, respectively, in the AIP group, while it was performed in 0% and 0.2% of the women with PPCS and Non-PPCS, respectively in the non-AIP group. Prior studies simply compared the hysterectomy rates between the two AIP groups but did not perform subgroup analysis based on the type of placenta implantation. Nevertheless, our results showed that the proportion of women with hysterectomy was lower than that reported in most other studies. Ling Li [16] reported that the hysterectomy rate was 8.47% in women with PPCS and 0% in women with Non-PPCS. Another study [27] in China reported hysterectomy rates were 11.9% (12/101) and 0.8% (3/369) in women with PPCS and Non-PPCS, respectively. However, there is also a report of a very low hysterectomy rate from Israel, which stated that only 1.2% of mothers with PP underwent a hysterectomy [28]. One possible and important reason for the low hysterectomy rate in our study is that obstetricians in our hospital use a random placenta margin incision [29] (also called an Ar’s incision), and we have found it may be a potentially valuable surgical procedure to control intraoperative and postoperative bleeding in pregnancies with complete placenta previa. We believe that retaining the uterus is of great
significance to young women who desire to preserve fertility, so it is acceptable to have an increased risk of postpartum hemorrhage and postpartum transfusion in women with PPCS if we can preserve the uterus.

Studies have shown that women who conceived with assisted reproductive technology (ART) procedures had an increased incidence of placenta previa regardless of the type of ART procedure [30, 31]. The mechanism for the development of the relationship between IVF-ET and PP is uncertain. One explanation is that ART procedures, maternal factors associated with sterility or a combination of both may increase the risk of PP in ART pregnancies. Varying theories have been developed around the effects of hormones on the endometrium, the effects of embryo transfer and the effects of changes in uterine contraction wave patterns [32]. There was no significant difference in IVF-ET between the PPCS and Non-PPCS groups because IVF-ET is a potential confounding factor, both HDCP and diabetes or GMD.

**Strengths and limitations of the study**

This is one of the largest studies investigating risk factors and clinical outcomes for PPCS and Non-PPCS placenta previa from a single medical center. The largest strength of this study is that the large sample size allowed us to study the association of PPCS and Non-PPCS and maternal and neonatal outcomes. However, there are several potential limitations to this study. First, despite this hospital being the largest maternity and child health care hospital in Foshan, selection bias is likely because this is a single-center study and because this is a retrospective review that relied on medical documentation and a database. Second, although we used ultrasound or MRI to distinguish between the front and back walls of the placenta, the division is not very precise since we did not measure the area of the anterior or posterior placenta walls. Larger studies are needed to determine the safety and efficacy of interventional radiology before this technique can be recommended for routine management of placenta implantation [33]. Therefore, this study does not use the following procedures: intraoperative internal iliac artery and/or postoperative uterine artery embolization and internal iliac artery or abdominal balloon occlusion. It would be prudent to compare hospitals at different levels or in different regions due to the presence of different surgical instruments, surgical
procedures, hemostasis procedures, surgical physician levels, and anesthetics. All of these potential limitations should be considered when interpreting the results of this study.

Conclusions
In conclusion, we investigated risk factors and maternal and neonatal outcomes in women with PPCS and Non-PPCS in a Chinese cohort. As the rate of CS increases with China’s universal two children policy, the rate of PP, especially PPCS, will most likely increase as well. Women with PPCS were more likely to have a premature birth, postpartum hemorrhage, hemorrhagic shock, an infant with worse Apgar scores, a longer hospital stay, and greater hospital expenses, and they were more likely to require a hysterectomy at the time of cesarean delivery than women with Non-PPCS. Health care providers should be aware of possible complications of PPCS to provide proper counseling to their patients.

Abbreviations
PP: Placenta previa; PPCS: PP with coverage of a uterine scar; Non-PPCS: PP without coverage of a uterine scar; MRI: Magnetic resonance imaging; CS: Cesarean section; IVF-ET: In vitro fertilization and embryo transfer; ACOG: American College of Obstetricians and Gynecologists; GDM: Gestational diabetes mellitus; HDCP: hypertensive disorder complicating pregnancy; OGGT: Oral Glucose Tolerance Test; SD: standard deviations; BMI: Body mass index; AIP: Abnormal invasive placenta

Declarations

Acknowledgements
We would like to thank Qili Yang and Xiaoli Li in data collection. The authors would like to thank all medical staff for their collaboration in clinical practice, particularly during data collection.

Author Contributions
JR and FD designed and implemented the study, conducted data analysis and write the manuscript; ZZ, CG, MH and LD designed the statistical analysis and help with data analysis; WS helped with analysis plan and result interpretation; GX and LZ designed the study and developed the manuscript. All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

Funding
The work was supported by the Science and Technology Innovation Project of Foshan (Grant No: 2017AG100261).

**Ethics approval and consent to participate**

The study was approved by the Human Subjects Committee of the Foshan Women and Children’s Hospital Affiliated with Southern Medical University. To ensure patient privacy, our data did not include the patient’s name, phone number, home address, or other sensitive information.

**Consent for publication**

Not applicable.

**Competing interests**

The authors have no conflicts of interest relevant to this article.

**References**

1. Nyberg DA: *Diagnostic imaging of fetal anomalies*: Lippincott Williams & Wilkins; 2003.

2. Silver RM: *Abnormal Placentation: Placenta Previa, Vasa Previa, and Placenta Accreta*. *Obstetrics and gynecology* 2015, **126**(3):654-668.

3. Crane JM, Van den Hof MC, Dodds L, Armson BA, Liston R: *Maternal complications with placenta previa*. *American journal of perinatology* 2000, **17**(2):101-105.

4. Knight M, Ukoss: *Peripartum hysterectomy in the UK: management and outcomes of the associated haemorrhage*. *BJOG : an international journal of obstetrics and gynaecology* 2007, **114**(11):1380-1387.

5. Grobman WA, Gersnoviez R, Landon MB, Spong CY, Leveno KJ, Rouse DJ, Varner MW, Moawad AH, Caritis SN, Harper M et al: *Pregnancy outcomes for women with placenta previa in relation to the number of prior cesarean deliveries*. *Obstetrics and gynecology* 2007, **110**(6):1249-1255.

6. Ananth CV, Demissie K, Smulian JC, Vintzileos AM: *Placenta previa in singleton and twin births in the United States, 1989 through 1998: a comparison of
risk factor profiles and associated conditions. *American journal of obstetrics and gynecology* 2003, 188(1):275-281.

7. Cresswell J, Ronsmans C, Calvert C, Filippi V: *Prevalence of placenta praevia by world region: a systematic review and meta-analysis*. *Trop Med Int Health* 2013, 18(6):712-724.

8. Fan D, Wu S, Wang W, Xin L, Tian G, Liu L, Feng J, Guo X, Liu Z: *Prevalence of placenta previa among deliveries in Mainland China: A PRISMA-compliant systematic review and meta-analysis*. *Medicine* 2016, 95(40):e5107.

9. Chattopadhyay SK, Kharif H, Sherbeeni MM: *Placenta praevia and accreta after previous caesarean section*. *European journal of obstetrics, gynecology, and reproductive biology* 1993, 52(3):151-156.

10. Daskalakis G, Simou M, Zacharakis D, Detorakis S, Akrivos N, Papantoniou N, Fouskakis D, Antsaklis A: *Impact of placenta previa on obstetric outcome*. *International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics* 2011, 114(3):238-241.

11. Rosenberg T, Pariente G, Sergienko R, Wiznitzer A, Sheiner E: *Critical analysis of risk factors and outcome of placenta previa*. *Arch Gynecol Obstet* 2011, 284(1):47-51.

12. Yu L, Hu K, Yang H: *A retrospective analysis on the pernicious placenta previa from 2008 to 2014*. *Zhonghua fu chan ke za zhi* 2016, 51(3):169-173.

13. Baldwin HJ, Patterson JA, Nippita TA, Torvaldsen S, Ibiebele I, Simpson JM, Ford JB: *Maternal and neonatal outcomes following abnormally invasive placenta: a population-based record linkage study*. *Acta obstetricia et gynecologica Scandinavica* 2017.

14. Butler E, Dashe J, Ramus R: *Association between maternal serum alpha-
fetoprotein and adverse outcomes in pregnancies with placenta previa. *Obstetrics and gynecology* 2001, 97(1):35-38.

15. Crane J, van den Hof M, Dodds L, Armson B, Liston R: Neonatal outcomes with placenta previa. *Obstetrics and gynecology* 1999, 93(4):541-544.

16. Li L: Analysis of risk factors for pernicious placenta praevia. *Int J Clin Exp Med* 2017, 10(2):3575-3581.

17. Dola C, Garite T, Dowling D, Friend D, Ahdoot D, Asrat T: Placenta previa: does its type affect pregnancy outcome? *American journal of perinatology* 2003, 20(7):353-360.

18. Obstetriciansgynecologists ACO: ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists Number 76, October 2006: postpartum hemorrhage. *Obstetrics & Gynecology* 2006, 108(4):1039.

19. Organization WH: Iron deficiency anemia. Assessment, prevention, and control. WHO/NHD/01.3. In.; 2001.

20. Sibai BM: Diagnosis and management of gestational hypertension and preeclampsia. *Obstetrics and gynecology* 2003, 102(1):181-192.

21. Lumbiganon P, Laopaiboon M, Gülmezoglu A, Souza J, Taneepanichskul S, Ruyan P, Attygalle D, Shrestha N, Mori R, Nguyen D et al: Method of delivery and pregnancy outcomes in Asia: the WHO global survey on maternal and perinatal health 2007-08. *Lancet* 2010, 375(9713):490-499.

22. Li HT, Luo S, Trasande L, Hellerstein S, Kang C, Li JX, Zhang Y, Liu JM, Blustein J: Geographic Variations and Temporal Trends in Cesarean Delivery Rates in China, 2008-2014. *Jama* 2017, 317(1):69-76.

23. 3Rd AA, Bowie JD, Rosenberg ER, Rauch RF: The fallacy of placental migration: effect of sonographic techniques. *Ajr American Journal of Roentgenology* 1985,
24. Khan AT, Stewart KS: Ultrasound placental localisation in early pregnancy. *Scottish Medical Journal* 1987, 32(1):19-21.

25. Tuzovic L: Complete versus incomplete placenta previa and obstetric outcome. *International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics* 2006, 93(2):110-117.

26. Sekiguchi A, Nakai A, Kawabata I, Hayashi M, Takeshita T: Type and location of placenta previa affect preterm delivery risk related to antepartum hemorrhage. *Int J Med Sci* 2013, 10(12):1683-1688.

27. Jang DG, We JS, Shin JU, Choi YJ, Ko HS, Park IY, Shin JC: Maternal outcomes according to placental position in placental previa. *Int J Med Sci* 2011, 8(5):439-444.

28. Walfisch A, Sheiner E: Placenta previa and immediate outcome of the term offspring. *Arch Gynecol Obstet* 2016, 294(4):739-744.

29. Fan D, Wu S, Ye S, Wang W, Wang L, Fu Y, Zeng M, Liu Y, Guo X, Liu Z: Random placenta margin incision for control hemorrhage during cesarean delivery complicated by complete placenta previa: a prospective cohort study. *The journal of maternal-fetal & neonatal medicine: the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet* 2018:1-8.

30. Pastore LM, Williams CD: Perinatal outcomes in singletons following in vitro fertilization: a meta-analysis. *Obstetrics and gynecology* 2004, 104(2):411; author reply 411-412.

31. Karami M, Jenabi E, Fereidooni B: The association of placenta previa and assisted reproductive techniques: a meta-analysis. *The journal of maternal-
32. Rombauts L, Motteram C, Berkowitz E, Fernando S: **Risk of placenta praevia is linked to endometrial thickness in a retrospective cohort study of 4537 singleton assisted reproduction technology births.** *Human reproduction (Oxford, England)* 2014, 29(12):2787-2793.

33. Jauniaux E, Alfirevic Z, Bhide AG, Belfort MA, Burton GJ, Collins SL, Dornan S, Jurkovic D, Kayem G, Kingdom J et al: **Placenta Praevia and Placenta Accreta: Diagnosis and Management: Green-top Guideline No. 27a.** *BJOG: an international journal of obstetrics and gynaecology* 2018.

### Tables

Table 1: Comparison of characteristics of patients with PPCS and Non-PPCS.

| Characteristics                  | Total (n=738) | PPCS (n=166) | Non-PPCS (n=572) | t/chi-square | P value |
|----------------------------------|--------------|--------------|------------------|--------------|---------|
| Maternal age mean ± SD, y        | 31.71±5.25   | 32.50±4.88   | 31.48±5.33       | -2.221       | 0.027   |
| Maternal BMI mean ± SD           | 26.06±3.11   | 26.49±3.35   | 25.93±3.03       | -2.046       | 0.041   |
| Gestational weeks mean ± SD      | 35.70±2.46   | 35.72±2.25   | 35.84±2.39       | -0.629       | 0.530   |
| Race/ethnicity (%)               |              |              |                  |              |         |
| Han Chinese                      | 726(98.4)    | 162(97.6)    | 564(98.6)        |              |         |
| National minority                | 12(1.6)      | 4(2.4)       | 8(1.4)           | 0.822        | 0.365   |
| BMI (%)                          |              |              |                  |              |         |
| <24                              | 185(25.1)    | 34(20.5)     | 151(26.4)        |              |         |
| 24 to 28                         | 375(50.8)    | 90(54.2)     | 285(49.8)        |              |         |
| ≥28                              | 178(24.1)    | 42(25.3)     | 136(23.8)        |              |         |
| Parity (%)                       |              |              |                  |              |         |
| 0                                | 231(31.3)    | 2(1.2)       | 229(40.0)        |              |         |
| 1                                | 411(55.7)    | 136(81.9)    | 275(48.1)        |              |         |
| 2                                | 85(11.5)     | 25(15.1)     | 60(10.5)         |              |         |
| 3                                | 11(1.5)      | 3(1.8)       | 8(1.4)           | 90.928       | <0.001  |
| Prior CS (%)                     |              |              |                  | 345.017      | <0.001  |
| No                               | 494(66.9)    | 12(7.2)      | 482(84.3)        |              |         |
| Yes                              | 244(33.1)    | 154(92.8)    | 90(15.7)         |              |         |
| IVF-ET (%)                       |              |              |                  | 3.355        | 0.067   |
| No                               | 677(91.7)    | 158(95.2)    | 519(90.7)        |              |         |
| Yes                              | 61(8.3)      | 8(4.8)       | 53(9.3)          |              |         |
| HDCP (%)                         |              |              |                  | 2.845        | 0.092   |
| No                               | 720(97.6)    | 159(95.8)    | 561(98.1)        |              |         |
| Yes                              | 18(2.4)      | 7(4.2)       | 11(1.9)          |              |         |
| Pre diabetes or GDM              |              |              |                  | 0.151        | 0.698   |
| No                               | 612(82.9)    | 136(81.9)    | 476(83.2)        |              |         |
| Yes                              | 126(17.1)    | 30(18.1)     | 96(16.8)         |              |         |

Note: n, number of observations; SD, standard deviation; a, BMI, body mass index, at delivery; b, BMI
before this delivery;

Data are mean±SD (independent t test) or n (%) (x² test) unless otherwise specified.

HDCP: hypertensive disorder complicating pregnancy; GDM: gestational diabetes mellitus.

Table 2: Comparison of abnormal invasive placenta in patients in the PPCS and Non-PPCS groups.

| Abnormal invasive placenta | Total (n=738) | PPCS (n=166) | Non-PPCS (n=572) | chi-square | P value |
|----------------------------|---------------|--------------|-------------------|------------|---------|
| Abnormal placenta          |               |              |                   |            |         |
| Total AIP                  | 151(20.5)     | 79(47.6)     | 72(12.6)          | 96.862     | <0.001  |
| Placenta accreta           | 57(7.7)       | 17(10.2)     | 40(7.0)           | 1.904      | 0.168   |
| Placenta increta or percreta | 94(12.7)   | 62(37.3)     | 32(5.6)           | 116.727    | <0.001  |
| Placenta position          |               |              |                   |            |         |
| Anterior                   | 202(27.4)     | 77(46.4)     | 125(21.9)         | 72.547     | <0.001  |
| Posterior                  | 352(47.8)     | 32(19.3)     | 320(56.1)         |            |         |
| Ante-posterior or laterally positioned | 182(24.7) | 57(34.3)     | 125(21.9)         |            |         |

Table 3: Comparison of pregnancy outcomes with and without abnormal invasive placenta in patients with PPCS and Non-PPCS.

| Maternal/Neonatal Outcomes | All (n=738) | PPCS (n=166) | Non-PPCS (n=572) | P-value |
|----------------------------|-------------|--------------|-------------------|---------|
| Maternal Gestational weeks |             |              |                   |         |
| <28                        | 0           | 0            | 0                 | 0.0     |
| 28-36                      | 111(68.1)   | 312(5.4)    | 59(75.6)          | 0.2     |
| 37-39                      | 49(30.1)    | 240(4.8)    | 17(21.8)          | 0.0     |
| >40                        | 3(1.8)      | 17(3.0)     | 2(2.6)            | 0.0     |
| Mode of delivery           |             |              |                   |         |
| Vaginal                    | 0           | 14(2.4)     | 0                 | 0.1     |
| Cesarean section           | 166(100.0)  | 558(9.7)    | 79(100.0)         | 0.0     |
| Intraoperativ e blood loss >1000 ml | 130(78.3) | 91(16.0)    | 70(88.6)          | 0.0     |
| Intraoperativ e blood loss >3000 ml | 49(29.5) | 17(3.0)     | 41(51.9)          | 0.0     |
| Bleeding within 2 hours after delivery, ml | 32.3±86.6 | 28.5±58.6 | 40.0±107.0 | 0.5 |
| Bleeding within 2 – 24 hours after delivery, ml | 162.3±357.5 | 49.9±58.5 | 209.9±41.7 | 0.7 |
| Postpartum hemorrhage      | 81(48.8)    | 90(15.7)    | 20(25.3)          | 0.3     |
| Condition                        | Result                  |
|---------------------------------|-------------------------|
| Transfusion                     | 58(35.2) 92(16.0) <0.00 | 33(42.3) 24(33.3) 0.2 58 25(28.7) 68(13.6) <0.001 |
| Hemorrhagic shock               | 14(8.4) 11(1.9) <0.01 | 12(15.2) 4(5.6) 0.0 2(2.3) 7(1.4) 0.5 29 |
| Postpartum anemia               | 39(23.5) 172(3.0) 0.1 99 | 19(24.1) 30(41.7) 0.0 20(23.0) 142(28.4) 0.2 97 |
| Hysterectomy                    | 5(3.0) 3(0.5) 0.0 6 | 5(6.3) 2(2.8) 0.3 0 1(0.2) 0.6 76 |
| Oligohydramnios                 | 9(5.4) 24(4.2) 0.5 2 | 4(5.1) 5(6.9) 0.6 5(5.7) 19(3.8) 0.3 97 |
| Hospital day                    | 12.7±9.2 11.4±12.2 12 | 14.5±10.0 13.2±13.0 0.5 11.0±8.0 11.1±12.0 0.8 96 |
| Hospitalization expenses, ¥     | 25097±9607 1386±901 2 | 1457±967 712±120 0.0 29756±9049 18359±8071 0.0 96 |
| Neonatal weight, mean ± SD      | 2702.8±577.4 2711.8±558.8 | 0.8 ± 0.7 ± 0.3 ± 0.7 ± 0.22 |
| Infant weight, g                | 0.7 ± 0.3 ± 0.7 ± 0.07 0.39 0.39 0.07 0.07 0.22 |
| <1500                           | 8(4.8) 23(4.1) 1 | 4(5.1) 1(1.4) 4(4.6) 22(4.4) |
| 1500-2500                       | 35(21.2) 145(8.2) 5.6 | 17(21.8) 21(29.6) 18(20.7) 124(25.0) |
| 2500-4000                       | 121(73.3) 396(6.9) 9.8 | 56(71.8) 49(69.0) 65(74.7) 347(70.0) |
| >4000                           | 1(0.6) 4(0.7) 0.8 1(1.3) 0 0 4(0.8) 0.4 0.03 |
| Intrauterine death              | 1(0.6) 1(0.7) 0.8 1(1.3) 0 0 4(0.8) 0.4 0.03 |
| Fetal distress                  | 60(36.1) 69(12.0) 0.0 | 29(36.7) 13(18.1) 0.0 31(35.6) 56(11.4) <0.001 |
| APGAR at 1 min                  | 8.7±2.1 9.3±2.1 0.00 | 8.2±2.5 9.0±2.1 0.6 57 9.1±1.6 9.4±1.6 0.1 11 |
| APGAR at 5 min                  | 9.2±1.5 9.6±1.6 0.00 | 9.1±1.6 9.7±1.3 0.0 9.3±1.3 9.6±1.6 0.1 48 |
| APGAR <7 at 1 min               | 27(16.6) 40(7.1) 0.00 | 21(27.6) 9(12.9) 0.0 6(6.9) 31(6.3) 0.8 |
| APGAR <7 at 5 min               | 5(3.0) 16(2.8) 0.02 | 2(2.6) 1(1.4) 0.6 3(3.4) 15(3.0) 0.8 43 |

Note: n, number of observations; SD, standard deviation; Data are mean±SD (independent t test) or n (%) (x² test or Fisher’s Exact Test).

Figures
Figure 1. Flow chart of study population.

Flow chart of the study population.
Figure 2

Box plots of intraoperative blood loss in the PPCS and Non-PPCS groups of women with and without AIP.